Hemorrhoid Drugs Market Analysis

The global hemorrhoid drugs market is segmented by end-user into hospitals, home care, specialty clinics, and others, out of which, the hospitals segment is anticipated to hold the largest share over the forecast period owing to the complications associated with the disease. The homecare segment is also estimated to witness significant growth by the end of 2037, owing to the increasing acceptance of homecare for the older patients. On the basis of disease type, the external hemorrhoids segment is anticipated to garner major market share over the forecast period, owing to the use of drugs as a treatment approach for external hemorrhoids, whereas, surgery is preferred for internal hemorrhoids.

Our in-depth analysis of the global market includes the following segments

By Drug Type	Topical Steroid Topical Anesthetics Others
By Disease Type	Internal Hemorrhoids External Hemorrhoids
By Distribution Channel	Offline Online
By End User	Hospitals Home Care Specialty Clinics Others

Frequently Asked Questions (FAQ)

Hemorrhoid Drugs Market size is likely to expand at significant growth rate during the forecast period i.e., between 2025-2037.

Growing prevalence of piles or hemorrhoids on the back of poor diet, lifestyle diseases and obesity, will propel the market growth.

Europe industry is likely to account for largest revenue share by 2037, on the back of high geriatric population, coupled with availability of advanced treatment options, better reimbursement policies and fast commercialization of novel products.

The major players in the market are Taro Pharmaceutical Industries Ltd., AstraZeneca, The Himalaya Drug Company, Panacea Biotec Ltd., Abbott Healthcare Private Limited, Sanofi-aventis Groupe, Pfizer Inc., Purdue Pharma L.P and others.

Hemorrhoid Drugs Market Analysis